

First half 2015: Record sales and solid profit growth

- Sales climb 14.8% in CHF
- Half-year local sales figure the highest in company history
- Renewed increase in operating and net income despite currency effects
- EBITDA at 26.9% and EBIT at 17.7% of sales
- Integration of American Peptide Company (APC) on track
- Investments in future growth in Europe and the US
- Very good results expected for 2015 as a whole

Bubendorf/Basel, August 28, 2015 – Bachem Group (SIX: BANB) increased its sales by about 15% to nearly 100 million CHF in the first half of 2015 (H1 2014: 86.7 million CHF). Group sales in local currency (LC) for the first half were higher than in any other half-year period since the company's founding. Generics sales rose by approx. 9% in LC to 49.3 million CHF and sales of research ingredients were also very strong in both the catalog products and custom synthesis business. Bachem achieved further stellar growth in the New Chemical Entities (NCEs) business, where sales rose by more than 22% in LC. Despite negative currency effects, EBITDA advanced to 26.8 million CHF and EBIT to 17.6 million CHF. Excluding last year's extraordinary gain of 2.0 million CHF on the divestment of the immunology product line, EBIT for the period was up by about 22%. Net income rose to 12.6 million CHF. In view of the pleasing first-half results, the orders on hand and current market developments, 2015 is expected to be a very good year.

	FIRST HALF-YEAR 2015	FIRST HALF-YEAR 2014	CHANGE IN %	
			CHF	LC
SALES (IN MCHF)	99.6	86.7	+14.8	+15.0
EBITDA (IN MCHF)	26.8	25.5	+4.9	+7.9
EBITDA IN % OF SALES	26.9	29.4		
EBIT (IN MCHF)	17.6	16.4	+7.1	+12.3
EBIT IN % OF SALES	17.7	18.9		
NET INCOME (IN MCHF)	12.6	12.4	+1.6	
NET INCOME IN % OF SALES	12.7	14.3		
EARNINGS PER SHARE (EPS – IN CHF)	0.93	0.92	+1.1	
CASH FLOW FROM OPERATING ACTIVITIES (IN MCHF)	29.4	19.3	+52.4	
NUMBER OF EMPLOYEES (IN FULL-TIME EQUIVALENTS)	821	662		

Outlook: Investments in future growth

Management priorities during the second half of the year will focus on the steady integration of APC and further investment in the capacity expansion at all existing sites, to accommodate future growth. Due to the record-high order backlog, Bachem will strengthen its teams in Switzerland, UK and the US. Management confirms its annual target for 2015. Based on a stable economic environment and current exchange rates, 2015 is expected to be a very good year. Including APC, the company expects sales growth in local currencies of about 10% and a further improvement in profitability.

The half-year report for 2015 can be downloaded from the following website:

www.bachem.com/half-year_report

Financial Calendar

March 11, 2016	Publication of Annual Report 2015; Media and Financial Analysts Conference
April 18, 2016	Annual General Meeting
August 26, 2016	Publication of Half-Year Report 2016

About Bachem

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and knowhow than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides**For more information:**

Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324

www.bachem.com

ir@bachem.com